Peringatan Keamanan

There is limited information regarding the LD50 of avelumab. Three patients who received a dose of avelumab that was 5% to 10% above the recommended dose experienced an overdose: the patients reported no symptoms and continued on avelumab therapy without requiring any treatment for the overdose. In the case of an overdose, patients should be closely monitored for signs or symptoms of adverse reactions. The treatment is directed to the management of symptoms.L48126

Avelumab

DB11945

biotech approved investigational

Deskripsi

Avelumab is a human IgG1 lambda monoclonal antibody that binds programmed cell death ligand-1 (PD-L1) to block its interaction with its receptors found on T cells and antigen-presenting cells.A261496 Avelumab was first approved by the FDA on March 23, 2017.A261496 On September 18 and December 18 of the same year, it was also granted approval by EMA L48126 and Health Canada,L48171 respectively. It is used in the treatment of Merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) The terminal half-life is approximately 6.1 days in patients with solid tumours receiving 10 mg/kg.[L48121]
Volume Distribusi The geometric mean volume of distribution at steady state for a subject receiving 10 mg/kg is 4.72 L.[L48121] Avelumab is expected to be distributed in the systemic circulation and, to a lesser extent, in the extracellular space.[L48171]
Klirens (Clearance) The total systemic clearance is approximately 0.59 L/day in patients with solid tumours receiving 10 mg/kg.[L48121]

Absorpsi

In patients who received doses ranging from 1 to 20 mg/kg every two weeks, avelumab exposure increased dose proportionally in the dose range of 10 to 20 mg/kg. Steady-state concentrations of avelumab were reached after approximately four to six weeks (two to three cycles) of repeated dosing, and the systemic accumulation was approximately 1.25-fold.L48121

Metabolisme

Avelumab undergoes nonspecific proteolytic degradation.L48121

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Makanan

1 Data
  • 1. Take with or without food.

Interaksi Obat

411 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Avelumab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Avelumab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Avelumab.
Estrone Estrone may increase the thrombogenic activities of Avelumab.
Estradiol Estradiol may increase the thrombogenic activities of Avelumab.
Dienestrol Dienestrol may increase the thrombogenic activities of Avelumab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Avelumab.
Mestranol Mestranol may increase the thrombogenic activities of Avelumab.
Estriol Estriol may increase the thrombogenic activities of Avelumab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Avelumab.
Quinestrol Quinestrol may increase the thrombogenic activities of Avelumab.
Hexestrol Hexestrol may increase the thrombogenic activities of Avelumab.
Tibolone Tibolone may increase the thrombogenic activities of Avelumab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Avelumab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Avelumab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Avelumab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Avelumab.
Zeranol Zeranol may increase the thrombogenic activities of Avelumab.
Equol Equol may increase the thrombogenic activities of Avelumab.
Promestriene Promestriene may increase the thrombogenic activities of Avelumab.
Methallenestril Methallenestril may increase the thrombogenic activities of Avelumab.
Epimestrol Epimestrol may increase the thrombogenic activities of Avelumab.
Moxestrol Moxestrol may increase the thrombogenic activities of Avelumab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Avelumab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Avelumab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Avelumab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Avelumab.
Biochanin A Biochanin A may increase the thrombogenic activities of Avelumab.
Formononetin Formononetin may increase the thrombogenic activities of Avelumab.
Estetrol Estetrol may increase the thrombogenic activities of Avelumab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Avelumab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Avelumab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Avelumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Avelumab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Avelumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Avelumab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Avelumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Avelumab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Avelumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Avelumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Avelumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Avelumab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Avelumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Avelumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Avelumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Avelumab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Avelumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Avelumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Avelumab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Avelumab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Avelumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Avelumab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Avelumab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Avelumab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Avelumab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Avelumab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Avelumab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Avelumab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Avelumab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Avelumab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Avelumab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Avelumab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Avelumab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Avelumab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Avelumab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Avelumab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Avelumab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Avelumab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Avelumab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Avelumab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Avelumab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Avelumab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Avelumab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Avelumab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Avelumab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Avelumab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Avelumab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Avelumab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Avelumab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Avelumab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Avelumab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Avelumab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Avelumab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Avelumab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Avelumab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Avelumab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Avelumab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Avelumab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Avelumab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Avelumab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Avelumab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Avelumab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Avelumab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Avelumab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Avelumab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Avelumab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Avelumab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Avelumab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Avelumab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Avelumab.

Target Protein

Programmed cell death 1 ligand 1 CD274

Referensi & Sumber

Artikel (PubMed)
  • PMID: 26014098
    Boyerinas B, Jochems C, Fantini M, Heery CR, Gulley JL, Tsang KY, Schlom J: Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57. doi: 10.1158/2326-6066.CIR-15-0059. Epub 2015 May 26.
  • PMID: 28274143
    Hamilton G, Rath B: Avelumab: combining immune checkpoint inhibition and antibody-dependent cytotoxicity. Expert Opin Biol Ther. 2017 Apr;17(4):515-523. doi: 10.1080/14712598.2017.1294156. Epub 2017 Feb 22.
  • PMID: 28456944
    Kim ES: Avelumab: First Global Approval. Drugs. 2017 May;77(8):929-937. doi: 10.1007/s40265-017-0749-6.
  • PMID: 30481100
    Collins JM, Gulley JL: Product review: avelumab, an anti-PD-L1 antibody. Hum Vaccin Immunother. 2019;15(4):891-908. doi: 10.1080/21645515.2018.1551671. Epub 2018 Dec 20.
  • PMID: 32266087
    Han Y, Liu D, Li L: PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020 Mar 1;10(3):727-742. eCollection 2020.

Contoh Produk & Brand

Produk: 3 • International brands: 0
Produk
  • Bavencio
    Solution • 20 mg / mL • Intravenous • Canada • Approved
  • Bavencio
    Injection, solution, concentrate • 20 mg/mL • Intravenous • EU • Approved
  • Bavencio
    Injection, solution, concentrate • 20 mg/1mL • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul